Published in Oncogene on November 07, 1996
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43
Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol (1998) 1.36
Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol (2000) 1.28
DNA methylation: an alternative pathway to cancer. Ann Surg (2001) 1.24
Molecular biology of Barrett's adenocarcinoma. Ann Surg (2001) 1.17
A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12
The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn (2006) 1.09
Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer (2008) 0.97
Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett (2008) 0.96
Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Mol Cytogenet (2012) 0.93
Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer (2003) 0.91
Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis (2014) 0.87
p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One (2008) 0.87
Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment. World J Gastroenterol (2011) 0.87
Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. Exp Biol Med (Maywood) (2014) 0.86
INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch (2004) 0.84
Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83
Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer (2014) 0.80
TissueCypher(™): A systems biology approach to anatomic pathology. J Pathol Inform (2015) 0.80
Esophageal cancer in kashmir (India): an enigma for researchers. Int J Health Sci (Qassim) (2009) 0.79
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci (2014) 0.79
A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev (2016) 0.79
Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus (2013) 0.78
Evidence for DNA damage checkpoint activation in barrett esophagus. Transl Oncol (2010) 0.78
A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res (2012) 0.76
Barrett's esophagus: model of neoplastic progression. World J Surg (2003) 0.75
Genetic control of the cell division cycle in yeast. Science (1974) 13.83
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Regulation of mating in the cell cycle of Saccharomyces cerevisiae. J Cell Biol (1977) 3.68
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Lead-contaminated house dust and urban children's blood lead levels. Am J Public Health (1996) 2.16
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res (2000) 2.13
p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology (1992) 2.03
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol (1986) 1.91
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res (1999) 1.90
Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest (1989) 1.83
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
A side-by-side comparison of dust collection methods for sampling lead-contaminated house dust. Environ Res (1995) 1.79
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res (1997) 1.67
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
p53-mutant clones and field effects in Barrett's esophagus. Cancer Res (1999) 1.61
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci U S A (1991) 1.53
17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res (1994) 1.52
Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res (1994) 1.49
Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene (1996) 1.46
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology (1994) 1.43
Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A (1993) 1.40
17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res (1991) 1.39
Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev (1996) 1.39
Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol (2000) 1.25
Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology (1990) 1.24
Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Nucleic Acids Res (1995) 1.24
Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology (1998) 1.24
Critical thinking disposition as a measure of competent clinical judgment: the development of the California Critical Thinking Disposition Inventory. J Nurs Educ (1994) 1.20
Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res (1996) 1.14
Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology (1991) 1.11
Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol (1988) 1.10
High-quality RNA and DNA from flow cytometrically sorted human epithelial cells and tissues. Biotechniques (2002) 1.08
The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer (1994) 1.05
Multiple keratoacanthomata. A unique case and review of the current classification. Acta Derm Venereol (1978) 1.04
Specialized metaplastic columnar epithelium in Barrett's esophagus. A comparative transmission electron microscopic study. Lab Invest (1989) 0.99
Impact of composting strategies on the treatment of soils contaminated with organic pollutants. Environ Pollut (2001) 0.99
Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res (1991) 0.99
Barrett's esophagus and adenocarcinoma. Annu Rev Med (1987) 0.99
Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc (1991) 0.97
Biomarkers in Barrett esophagus. Mayo Clin Proc (2001) 0.97
Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res (1992) 0.97
Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. Gastroenterology (1989) 0.97
Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol (1994) 0.97
Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer (2000) 0.94
[Effects of novobiocin on the functioning of the liver. II. Experimental study]. Rev Fr Etud Clin Biol (1967) 0.92
Application of a luminescence-based biosensor for assessing naphthalene biodegradation in soils from a manufactured gas plant. Environ Pollut (2009) 0.90
p53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol (2001) 0.89
Study of tinea capitis in Philadelphia using case and control groups. Public Health Rep (1968) 0.87
Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci (1989) 0.86
Actinic granuloma in association with giant cell arteritis: are both caused by sunlight? Pathology (1997) 0.86
Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas (1995) 0.86
Flow-cytometric DNA content analysis of esophageal squamous cell carcinomas. Gastroenterology (1991) 0.85
Barrett's esophagus: the biology of neoplastic progression. Gastroenterol Clin Biol (1994) 0.85
Escherichia coli survival in lettuce fields following its introduction through different irrigation systems. J Appl Microbiol (2011) 0.84
Loss of heterozygosity in childhood de novo acute myelogenous leukemia. Blood (2001) 0.83